# A Study to Evaluate the Efficacy and Safety of Semorinemab in Patients With Prodromal to Mild Alzheimer's Disease

> **NCT03289143** · PHASE2 · TERMINATED · sponsor: **Genentech, Inc.** · enrollment: 457 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** Semorinemab
- **DRUG:** Placebo
- **DRUG:** [18F]GTP1

## Key facts

- **NCT ID:** NCT03289143
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-10-04
- **Primary completion:** 2021-01-15
- **Final completion:** 2021-01-15
- **Target enrollment:** 457 (ACTUAL)
- **Why stopped:** Study was terminated during Open Label Extension period because analyses of placebo-controlled Blinded portion of study did not show any evidence of clinical efficacy or modulation of accumulation of tau PET signal at any of the doses studied.
- **Last updated:** 2022-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03289143

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03289143, "A Study to Evaluate the Efficacy and Safety of Semorinemab in Patients With Prodromal to Mild Alzheimer's Disease". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03289143. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*